Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
There are 2 phases in this study: Phase 1 (dose escalation) and Phase 2 (dose expansion).
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of
lenvatinib and Xeloda (capecitabine) that can be given to patients with advanced cancer. The
goal of Phase 2 of this study is to learn if the dose of lenvatinib and capecitabine found in
Phase 1 can help to control advanced cancer.
The safety of this drug combination will be studied in both phases of the study.